ERBITUX: payments to doctors
Payments that named ERBITUX as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $186K
- Providers
- 1,529
- Transactions
- 2,892
- Average per transaction
- $64
The per-transaction average — $64 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,529 providers the average total is $122, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Lilly USA, LLC | $157,437 | 84.5% |
| Merck Kgaa | $27,198 | 14.6% |
| Merck, S.l.u. | $1,636 | 0.9% |
| E.r. Squibb & Sons, L.L.C. | $43 | 0.0% |